

Product Sheet

Cynomolgus_BCMA CHO-K1 Cell Line

Catalog number: GM-C47990

Version 3.3.1.260910

Description	Cynomolgus_BCMA CHO-K1 Cell Line is a clonal stable CHO-K1 cell line that constitutively expresses the cynomolgus BCMA gene, constructed using lentiviral technology.
Quantity	5E6 Cells per vial, 1 mL
Product Format	1 vial of frozen cells
Shipping	Shipped on dry ice
Storage Conditions	Liquid nitrogen immediately upon receipt
Target	Cynomolgus_BCMA
Gene ID/Uniprot ID	A0A2K5UD97(AA Met 1 - Asn 52)
Host Cell	CHO-K1
Recovery Medium	F12K+10% FBS+1% P.S
Growth medium	F12K+10% FBS+1% P.S+4 µg/mL Puromycin
Note	None
Freezing Medium	90% FBS+10% DMSO
Growth properties	Adherent
Growth Conditions	37°C, 5% CO ₂
Mycoplasma Testing	The cell line has been screened to confirm the absence of Mycoplasma species.
Safety considerations	Biosafety Level 2
Note	It is recommended to expand the cell culture and store a minimum of 10 vials at an early passage for potential future use.

Materials

Reagent	Manufacturer/Catalogue No.
F12K	BOSTER/PYG0036
Fetal Bovine Serum	ExCell/FSP500
Pen/Strep	Thermo/15140-122
Puromycin	Genomeditech/ GM-040401
Anti-BCMA hIgG1 Antibody(Belantamab)	Genomeditech/ GM-52396AB

Figures




Figure 1 | Cynomolgus_BCMA CHO-K1 Cell Line (Cat. GM-C47990) was determined by flow cytometry using Anti-BCMA hIgG1 Antibody(Belantamab) (Cat. [GM-52396AB](#)).

Cell Recovery

Recovery Medium: F12K+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

- Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).
- Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
- Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.
- Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.

- e) Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

- Centrifuge at 176 x g for 3 minutes to collect cells.
- Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.
- Aliquot 1 mL into each vial.
- Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: F12K+10% FBS+1% P.S+4 µg/mL Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

- Remove and discard culture medium.
- Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.
- Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 2 to 3 minutes at 37°C).
- Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.
- After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:4 - 1:5 is recommended

Medium Renewal: Every 2 to 3 days

Notes

- After the stabilization of the cell condition, there will be fewer dead cells post-passage, the cell growth rate will tend to stabilize, cell morphology will become uniform, and the cells will appear robust.

Sequence

BCMA(TNFRSF17) [A0A2K5UD97 \(ECD\)](#)

MLQMARQCSQNEYFDSLLHDCKPCQLRCSSTPPLTCQRYCNASMTNSVKGMN

Related Products

CD40:CD40L

H_CD40(TNFRSF5) Reporter 293 Cell Line	H_CD40(TNFRSF5) Reporter Jurkat Cell Line
Cynomolgus_CD40 CHO-K1 Cell Line	Cynomolgus_CD40L CHO-K1 Cell Line
H_CD40(TNFRSF5) CHO-K1 Cell Line	H_CD40(TNFRSF5) HEK-293 Cell Line
H_CD40L CHO-K1 Cell Line	H_CD40L HEK-293 Cell Line
Mouse_CD40L CHO-K1 Cell Line	Rabbit_CD40L NIH-3T3 Cell Line
Anti-CD40 hIgG1 Reference Antibody (Sotibio)	Anti-CD40 hIgG1 Reference Antibody (Tenebio)
Anti-CD40L hIgG1 Reference Antibody (Frebio)	Anti-H_CD40 hIgG1 Antibody(APX005M)
Anti-H_CD40 hIgG1 Antibody(ravagalimab)	Anti-H_CD40L hIgG1 Antibody(dapirolizumab)
Anti-H_CD40L hIgG1 Antibody(frexalimab)	
Biotinylated Human CD40 Protein; His-Avi Tag	Cynomolgus CD40 Protein; His Tag
Human CD40 Protein; His Tag	Human CD40L Protein; His Tag
IFN-α	
IFNα Reporter HEK-293 Cell Line	IFNα Reporter MDCK Cell Line
IFNα Reporter THP1 Cell Line	
BCMA:BAFFR:TACI	
H_BAFFR Jurkat Blockade Reporter Cell Line	H_BAFFR Reporter Cell Line
H_BCMA Reporter 293 Cell Line	H_BCMA Reporter Cell Line
H_TACI Reporter Cell Line	Cynomolgus_BCMA CHO-K1 Cell Line (Low Expression)
Cynomolgus_BCMA HEK-293 Cell Line	H_BAFFR CHO-K1 Cell Line
H_BAFFR HEK-293 Cell Line	H_BCMA CHO-K1 Cell Line (Low Expression)
H_BCMA HEK-293 Cell Line	Membrane Bound H_APRIL(Trimer) HEK-293 Cell Line
Anti-BAFF hIgG1 Antibody(belimumab)	Anti-BAFFR hIgG1 Antibody(ianalumab)
Anti-BCMA hIgG1 Antibody(Belantamab)	Anti-BCMA hIgG1 Antibody(SEA-BCMA)
Anti-BCMA hIgG4 Antibody(BCMB69)	Anti-CD3E×BCMA hIgG4 Reference Antibody (Tecbio)
Anti-TNFSF13B(BAFF) hIgG1 Reference Antibody (Belibio)	
Biotinylated Human BAFF Protein; His-Avi Tag	Biotinylated Human BCMA Protein; His-Avi Tag
Cynomolgus BAFF Protein; His Tag	Cynomolgus BCMA Protein; hFc Tag
Cynomolgus BCMA Protein; His Tag	Human APRIL Protein; hFc Tag
Human BCMA Protein; hFc Tag	Human BCMA Protein; His Tag
Mouse BAFF Protein; His Tag	
BDCA2(CLEC4C)	
H_BDCA2 Reporter DDX35TM Jurkat Cell Line	H_BDCA2 Reporter Jurkat Cell Line
Cynomolgus_BDCA2 CHO-K1 Cell Line	Cynomolgus_BDCA2 Jurkat Cell Line
H_BDCA2 CHO-K1 Cell Line	H_BDCA2 HEK-293 Cell Line
H_BDCA2 Jurkat Cell Line	
Anti-H_BDCA2 hIgG1 Antibody(Litifilimab)	
Cynomolgus BDCA2 Protein; His Tag	Human BDCA2 Protein; His Tag
CD3	
Cynomolgus_CD3D CD3E Reporter Jurkat(CD3DE KO) Cell Line	Jurkat CD3-BsAb Reporter Cell Line

Cynomolgus_CD3 HEK-293 Cell Line	Cynomolgus_CD3E(Membrane Bound ECD) CHO-K1 Cell Line
H_CD3 CHO-K1 Cell Line	H_CD3 HEK-293 Cell Line
H_CD3(TCR V2) CHO-K1 Cell Line	H_CD3(TCR V2) HEK-293 Cell Line
H_CD3(TCR α β delta V) HEK-293 Cell Line	H_CD3D CD3E KO Jurkat Cell Line
H_CD3E KO Jurkat Cell Line	H_CD3E(Membrane Bound ECD) CHO-K1 Cell Line
Mouse_CD3 HEK-293 Cell Line	
Anti-CD19 $\times$ CD3 hIgG1 Antibody[PIT-565(CD58 K34A)]	Anti-CD3 epsilon hIgG1 Antibody [OKT-3 (muromonab)]
Anti-CD3 hIgG1 Antibody(CH2527)	Anti-CD3 $\times$ CD20 hIgG1 Bispecific Antibody (Epcobio)
Anti-CD3 $\times$ FCRL5 hIgG1 Bispecific Antibody(cevostamab)	Anti-CD3E $\times$ BCMA hIgG4 Reference Antibody (Tecbio)
Anti-CD3E $\times$ DLL3 hIgG1 Bispecific Antibody(Tarlabio)	Anti-CD3E $\times$ MUC17 hIgG1 Bispecific Antibody(Vepsitbio)
Anti-mouse CD3 ϵ mIgG2a Antibody(145-2C11)	

License Agreement:

By purchasing and using this cell line product, the user voluntarily agrees to accept and abide by the following policies:

- This cell line product is restricted to research use only and shall not be used for any commercial purposes.
- This product is strictly prohibited from being used in the diagnosis or treatment of human or animal diseases, and shall not be directly used in experiments involving humans.
- Users and their contractors engaged for their benefit may use this material and its derivatives only within the agreed research scope; modification of the material is not permitted, nor may it be distributed, sold, transferred, or otherwise provided to any other entity (including affiliates).
- If use beyond the above scope is required, prior written permission from Genomeditech (Shanghai) Co.,Ltd. must be obtained. For details, please contact Genomeditech (Shanghai) Co.,Ltd.